Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA surgery"
DOI: 10.1001/jamasurg.2020.2286
Abstract: Importance Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel (GA) are first-line chemotherapy regimens for pancreatic cancer. Their relative efficacy in the setting of localized disease is unknown. Objective To evaluate… read more here.
Keywords: response; line; first line; folfirinox ... See more keywords
FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06.
Sign Up to like & getrecommendations! Published in 2020 at "Pancreas"
DOI: 10.1097/mpa.0000000000001692
Abstract: OBJECTIVES The multidrug regimen with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is widely used for recurrent pancreatic cancer after pancreatic resection. However, there are concerns about severe toxicities and poor tolerability of FOLFIRINOX in these… read more here.
Keywords: cancer; study; folfirinox; pancreatic resection ... See more keywords
Abstract B48: Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.panca19-b48
Abstract: Background: Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality, with dismal 5-year prognosis of 8%, in part due to poor response to available therapies. Thus, new systemic cancer control therapies are in… read more here.
Keywords: sema4d; murine; murine model; plexin ... See more keywords
Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211033704
Abstract: Background: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression… read more here.
Keywords: tumor progression; folfirinox; early tumor; tp53 ... See more keywords
Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.8_suppl.245
Abstract: 245Background: While FOLFIRINOX is a standard treatment option for advanced pancreas cancer there is little data describing utilization and effectiveness in routine clinical practice. Here we report practice patterns and outcomes in the general population… read more here.
Keywords: advanced pancreas; pancreas cancer; folfirinox; uptake effectiveness ... See more keywords
Folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic adenocarcinoma: A propensity matched analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.402
Abstract: 402Background: Comparative effectiveness of FOLFIRINOX and Gemcitabine/nab-paclitaxel (G-nP) in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA), remains unknown. The aim o... read more here.
Keywords: nab paclitaxel; neoadjuvant treatment; folfirinox; gemcitabine nab ... See more keywords
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.89
Abstract: 89Background: Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR). FOLFIRINOX has been used in first line therapy in other GI cancers (i.e pancreatic and CRC) with… read more here.
Keywords: phase; line; first line; folfirinox ... See more keywords
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2021.27.10.1367
Abstract: BACKGROUND: Pancreatic cancer is associated with low median overall survival. Combination chemotherapy regimens FOLFIRINOX and gemcitabine with nab-paclitaxel (GemNab) are the new adjuvant treatment standards for resectable pancreatic cancer. PRODIGE-24 and APACT trials demonstrated superior… read more here.
Keywords: cost effectiveness; cost; folfirinox; pancreatic cancer ... See more keywords
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15734
Abstract: Background: Pancreatic cancer is one of the most recalcitrant cancers, and more effective therapy is needed. Pre-clinical studies have shown that patient-derived orthotopic xenograft (PDOX) mouse models of pancreatic cancer are effectively treated with oral… read more here.
Keywords: folfirinox; pancreatic cancer; patient; cancer ... See more keywords
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.898498
Abstract: Background Biomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response… read more here.
Keywords: folfirinox; tumor progression; response; overall survival ... See more keywords
Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1050070
Abstract: Introduction FOLFIRINOX (the combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is the preferred systemic regimen for locally advanced pancreatic cancer (LAPC). Furthermore, stereotactic body radiation therapy (SBRT) is a promising treatment option for achieving local… read more here.
Keywords: folfirinox; followed sbrt; induction folfirinox; folfirinox followed ... See more keywords